Retatrutide vs Zepbound: Triple vs Dual Agonist

Retatrutide produced 28.7% body weight loss in its Phase 2 trial at the 12mg dose over 48 weeks. That's the highest weight loss ever recorded for any obesity medication in clinical trials — and the curve hadn't fully plateaued, suggesting even greater losses with longer treatment.

Zepbound (tirzepatide) at 22.5% in SURMOUNT-1 was already the best-in-class among approved drugs. Retatrutide pushes the boundary an additional 6+ percentage points beyond that.

For a 240 lb patient, the difference is roughly:

• Zepbound: ~54 lbs lost
• Retatrutide: ~69 lbs lost

Critical caveat: The 28.7% number comes from a Phase 2 trial — smaller, shorter, and in a more selected patient population than Phase 3. Phase 2 results don't always replicate in larger Phase 3 trials. The TRIUMPH Phase 3 program will confirm whether this level of efficacy holds. Even if the number comes down slightly in Phase 3, retatrutide would still likely beat Zepbound.

Zepbound (tirzepatide): Dual GIP + GLP-1 agonist — activates two incretin receptors for appetite suppression, improved insulin sensitivity, and enhanced fat metabolism.

Retatrutide: Triple GIP + GLP-1 + glucagon agonist — everything Zepbound does, plus glucagon receptor activation.

What glucagon adds:

• Increased energy expenditure: Glucagon drives thermogenesis — your body burns more calories at rest
• Enhanced fat oxidation: Glucagon mobilizes fat stores more aggressively than GIP/GLP-1 alone
• Unique liver fat reduction: Glucagon receptor activation in the liver drives dramatic reductions in hepatic fat (37% in Phase 2)

The historical concern: Glucagon agonism raises blood glucose — that's why it was avoided in obesity drugs for decades. Retatrutide threads the needle: the GLP-1 and GIP components offset the glucose-raising effect, keeping blood sugar controlled while capturing glucagon's fat-burning benefits. In the Phase 2 trial, blood sugar actually improved despite the glucagon component.

This may be retatrutide's most important differentiator beyond raw weight loss.

MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) affects approximately 30% of adults worldwide and is the leading cause of liver transplants in the U.S. Current GLP-1 drugs reduce liver fat modestly. Retatrutide is different.

Retatrutide Phase 2 results on liver fat:

• Up to 37% reduction in liver fat content
• Many participants achieved complete resolution of steatosis (fat content below the diagnostic threshold)
• This effect is driven primarily by the glucagon receptor component, which directly activates hepatic fat oxidation

Zepbound reduces liver fat through weight loss and improved metabolic parameters, but the reduction is more modest and indirect compared to retatrutide's direct glucagon-mediated mechanism.

Why this matters: For patients with obesity and fatty liver disease, retatrutide could be uniquely valuable — treating both conditions with one drug through distinct mechanisms. Lilly is running dedicated MASLD Phase 3 trials for retatrutide, which could lead to a separate FDA approval for liver disease.

Zepbound is available now — approved since November 2023, prescribed at weight management clinics nationwide, with stable supply through pharmacies and LillyDirect.

Retatrutide is in Phase 3 trials (the TRIUMPH program). The timeline:

• Phase 3 results: Expected 2026–2027
• FDA submission: Would follow positive Phase 3 data — likely late 2027
• FDA review: Standard review takes 10–12 months
• Realistic approval and launch: 2027–2028 at the earliest

That's 2+ years away. Clinical development timelines frequently slip — unexpected safety signals, manufacturing challenges, FDA questions, or enrollment delays can all push dates back. Planning your health around a drug that hasn't completed Phase 3 trials is not advisable.

The math is simple: If you start Zepbound today and achieve 22.5% weight loss over the next 18 months, you'll have already transformed your health before retatrutide reaches the market. Don't let the perfect be the enemy of the available.

Eli Lilly is building a tiered obesity treatment portfolio:

1. Foundayo (orforglipron): Oral pill, 12.4% weight loss — positioned for convenience, maintenance, and cost-sensitive patients ($149–349/mo)
2. Zepbound (tirzepatide): Weekly injection, 22.5% weight loss — the current flagship for active weight loss
3. Retatrutide: Weekly injection, 28.7% weight loss — future flagship for maximum possible loss and liver disease

The intended patient journey: Start with Zepbound (or retatrutide, once available) for aggressive weight loss. Step down to Foundayo for long-term oral maintenance. This keeps patients in the Lilly ecosystem from treatment initiation through lifelong maintenance.

When retatrutide launches: Zepbound becomes the mid-tier option. Retatrutide sits at the top for patients who need maximum efficacy or have comorbid liver disease. Foundayo remains the oral maintenance option. Doctors will have an unprecedented range of tools from a single company.

Competitive implication: With retatrutide, Lilly would have both the most effective injectable (retatrutide) and the most convenient oral (Foundayo) in their portfolio — a formidable position against Novo Nordisk's CagriSema.